Author

Beatriz Baragaña

University of DundeeORCID 0000-0002-0959-1113Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Microbiology· 2 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Assay:metagenomics· 1 Organism:mouse· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

John M. PostiD· 2 shared Kevin D. ReadiD· 2 shared A. Kenneth MacLeodiD· 1 shared Alasdair Smith· 1 shared Alice DawsoniD· 1 shared Alice H. CostainiD· 1 shared Amy TavendaleiD· 1 shared Andrew PlateriD· 1 shared

Activity by Year

2025-2025 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 22 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

John M. PostORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Use of a cytochrome P450 humanised mouse model to refine schistosomiasis drug discovery.

Sarah D. Davey, Josephine Forde-Thomas, Benjamin J. Hulme, Kristin Lees, Alice H. Costain, Mary Evans, Gabriel Rinaldi, Laura Frame, Laste Stojanovski, Frederick R. C. Simeons, Amy Tavendale, A. Kenneth MacLeod, Rémi Pichon, Yi‐Hsuan Lee, Oktawia Polak, , Karl F. Hoffmann

A cytochrome P450 humanised mouse model is used to study Schistosoma mansoni development, schistosomiasis, drug metabolism and drug efficacy.

bioRxiv · Nov 27, 2025 · PreprintPharmacology & Toxicology

Mechanistic Insights into Dual-Active Liver and Blood-Stage Antiplasmodials

Mukul Rawat, Nonlawat Boonyalai, Cindy Smidt, Madeline R. Luth, Daisy Chen, Andrew Plater, John M. Post, De Lin, Joel McMillan, T.C. Eadsforth, Sonia Moliner Cubel, Oliver Billker, Julian C. Rayner, Francisco‐Javier Gamo, Beatriz Baragaña, , Lee M

This paper identifies targets of dual-active antimalarials by evolving resistance to nine compounds and validates them using CRISPR and molecular docking.

mBio · Nov 24, 2025Peer-reviewedMicrobiology

Design and development of lysyl tRNA synthetase inhibitors, for the treatment of tuberculosis

Susan H. Davis, Michael Mathieson, Kirsteen I. Buchanan, Alice Dawson, Alasdair Smith, Mattia Cocco, Fábio K. Tamaki, John M. Post, Beatriz Baragaña, Chimed Jansen, Michael Kiczun, Fabio Zuccotto, Gavin Wood, Paul Scullion, Peter C. Ray, , Laura A. T. Cleghorn

The paper describes the development of lysyl tRNA synthetase inhibitors for tuberculosis treatment, optimizing compounds for preclinical and potential clinical use.

Journal of Medicinal Chemistry · Aug 1, 2025Peer-reviewedMicrobiology